Ronald Balassanian
A5073258435- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- AI in cancer detection
- Lymphoma Diagnosis and Treatment
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Radiology practices and education
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Viral-associated cancers and disorders
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- BRCA gene mutations in cancer
- Fungal Infections and Studies
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Colorectal Cancer Screening and Detection
- Ecology and Conservation Studies
- Cutaneous lymphoproliferative disorders research
- Molecular Biology Techniques and Applications
University of California, San Francisco
2015-2024
Beth Israel Deaconess Medical Center
2006-2024
The University of Texas MD Anderson Cancer Center
2020-2024
Università Cattolica del Sacro Cuore
2018-2024
Massachusetts General Hospital
2016-2024
Faculty of Media
2023
City College of San Francisco
2020-2023
San Francisco General Hospital
2022
University of Minnesota
2018-2022
Charles River Laboratories (Netherlands)
2018-2021
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group neoplastic lesions ducts. The goal for management DCIS is to prevent development invasive cancer. This manuscript focuses on NCCN Guidelines Panel recommendations workup, primary treatment, risk reduction strategies, and surveillance specific DCIS.
These NCCN Guidelines Insights highlight the important updates/changes to surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in 1.2017 version of Breast Cancer. This report summarizes these updates discusses rationale behind them. Updates on new drug approvals, not available at press time, can be found most recent guidelines NCCN.org.
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This article outlines NCCN Guidelines specific that locoregional (restricted one region body), discusses clinical stage I, II, IIIA (T3N1M0) tumors. For on adjuvant therapy after II for other stages cancer,...
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This portion NCCN Guidelines discusses recommendations specific locoregional clinical stage I, II, IIIA (T3N1M0) tumors.
These NCCN Guideline Insights highlight the important updates to systemic therapy recommendations in 2016 Guidelines for Breast Cancer. In most recent version of these guidelines, Cancer Panel included a new section on principles preoperative therapy. addition, based evidence, panel updated women with hormone receptor–positive breast cancer adjuvant and metastatic disease settings patients HER2-positive cancer. This report summarizes discusses rationale behind them.
<h3>Importance</h3> Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast trials. <h3>Objective</h3> To compare RCB between randomized control and investigational treatments within subtypes explore relationship with survival. <h3>Design, Setting, Participants</h3> The I-SPY2 is a multicenter, platform adaptive, clinical trial US that compares, by subtype, agents combination chemotherapy vs alone adult women stage 2/3 at high risk early...
Cell block (CB) techniques for fine-needle aspiration biopsies (FNABs) vary. A direct comparison of CB with statistical validation was performed to identify the best method.Three were compared: 1) FNAB rinsed in saline and clotted plasma thrombin (SPT); 2) formalin HistoGel (HG); 3) formalin, centrifuged, pellet captured a collodion bag (ColB). on 35 random surgical specimens smears each technique. randomized blinded review hematoxylin eosin-stained slides case scored scale 1 3 cellularity,...
Breast cancer patients with estrogen receptor (ER)–positive disease have a continuous long-term risk for fatal breast cancer, but the biological factors influencing this are unknown. We aimed to determine whether high intratumor heterogeneity of ER predicts an increased (25 years) cancer. The STO-3 trial enrolled 1780 postmenopausal lymph node–negative randomly assigned receive adjuvant tamoxifen vs not. fraction cells each intensity level was scored by pathologists, and calculated using...
Scant published data exist on redesigning pathology practice based error data. In this first step of an Agency for Healthcare Research and Quality patient safety project, we measured the performance metrics thyroid gland fine-needle aspiration, performed root cause analysis to determine causes error, proposed error-reduction initiatives address specific errors. Eleven cytologists signed out 1,543 aspirates in 2 years, surgical follow-up was obtained 364 patients. Of patients, 91 (25.0%) had...
Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk mortality than non-Hispanic White women. Studies U.S. Latinas women reported high incidence HER2 positive (+) tumors; however, factors contributing this observation unknown. Genome-wide genotype data for 1,312 patients from Peruvian Genetics Genomics Breast Cancer Study (PEGEN-BC) were used estimate genetic ancestry. We tested association between status...
Our objective was to determine whether the Toyota Production System process redesign resulted in diagnostic error reduction for patients who underwent cytologic evaluation of thyroid nodules. In this longitudinal, nonconcurrent cohort study, we compared frequency a aspiration service before and after implementation initiatives consisting adoption standardized terminology scheme an immediate interpretation service. A total 2,424 aspiration. Following standardization, false-negative rate...
The Paris System for Reporting Urinary Cytology (TPS) published in 2016 provides a standardized approach to evaluating urine cytology. In the authors' practice, TPS-like was adopted 2012 using similarly defined cytologic criteria and correlating cystoscopic findings, they also began incorporating use of cell block (CB) material. objective current study assess whether this with CB, as well direct implementation TPS, improved diagnostic value cytology.In total, 188 consecutive cytology...
Timeliness is an important and recognized measure of health care quality. Multiple organizations worldwide have published timeliness targets for breast cancer care. We performed the first comparison patient wait times utilization patterns palpable mass diagnosis treatment with regard to biopsy method.Palpable masses in women biopsied via a fine-needle aspiration (FNA) or core at 2 affiliated academic medical centers 2009 were analyzed if subsequently treated excision neoadjuvant therapy....
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point trials. However, there is controversy regarding whether definition of pCR should exclude or permit presence residual ductal carcinoma situ (DCIS).To examine association DCIS surgical specimens for points to inform standards assessment pathologic response.The study team analyzed NAC 3-year event-free (EFS), distant...